Please assess the completion status of the following clinical trial:

Trial Title: Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women, age between 18 and 50 years~* Ethnicity has a match with the intended profile for the site~* Weight \< 140kg or 310lbs~* Pre- or peri-menopausal as indicated by clinical evaluation or Follicle Stimulating Hormone (FSH) level \< 40 IU/L~* Willing and able to attend all study visits~* Willing and able to complete Menstrual Blood Loss (MBL) assessment with Alkaline Hematin (AH) method~* Willing and able to use reliable contraception methods~* Uterine size \< 24 weeks~* Cervical cell assessment by Pap smear: Normal, Low Grade Squamous Intraepithelial Lesion (SIL), Low risk Human Papillomavirus (HPV) or Atypical Squamous Cells of Uncertain Significance (ASCUS) subtypes of cervical tissue~* MR-HIFU device accessibility to fibroids such that at least 50% of the total fibroid volume can be treated.~* Fibroids selected for treatment meeting the following criteria (further extrapolated in the protocol):~  1. Total planned ablation volume of all fibroids should not exceed 250 ml and~ 2. No more than 5 fibroids should be planned for ablation and~ 3. Dominant fibroid (diameter) is greater than or equal to 3 cm and~ 4. Completely non-enhancing fibroids should not be treated as the identification of treated volume becomes ambiguous~* Patient's self-assessment indicates that she has had episodes of heavy menstrual bleeding in the past 6 months.~* Menstrual Blood Loss (MBL) ≥150 ml and ≤ 500 ml~Exclusion Criteria:~* Other Pelvic Disease (Other mass, endometriosis, ovarian tumor, acute pelvic disease, significant adenomyosis)~* Desire for future pregnancy~* Significant systemic disease even if controlled~* Positive pregnancy test~* Hematocrit \< 25%~* Extensive scarring along anterior lower abdominal wall (\>50% of area)~* Surgical clips in the potential path of the HIFU beam~* MRI contraindicated~* MRI contrast agent contraindicated (including renal insufficiency)~* Calcifications around or throughout uterine tissues that may affect treatment~* Communication barrier~* Highly perfused or brighter than myometrium in T2-weighted MRI (according to the T2 contrast obtained using the Philips MR-HIFU MR protocol) fibroids~* Fibroids not quantifiable on MRI (e.g. multi-fibroid cases where volume measurements are not feasible)~* Menses lasting \> 7 days or intermenstrual bleeding (patient can be included if there is endometrial biopsy within 6 months to exclude malignancy)~* Patient is currently on hormonal medication for fibroids or has a hormonal medication history as described below:~  1. 1-month Lupron dose or equivalent: less than 1 month prior to MBL measurement or~ 2. 3-month Lupron dose or equivalent: less than 3 months prior to MBL measurement or~ 3. Depo Provera or equivalent: less than 6 months prior to MBL measurement

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- MR-HIFU treatment (Type: EXPERIMENTAL): Patients receiving MR-HIFU treatment
- Sham Treatment (Type: SHAM_COMPARATOR): Patients receiving sham treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).